cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Stockal+Disclaimer.pdf
18 own
13 watching
Current Price
$56.41
$0.5
(0.89%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
5,591.55M
52-Week High
52-Week High
110.25000
52-Week Low
52-Week Low
25.98000
Average Volume
Average Volume
0.83M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization5,591.55M
icon52-Week High110.25000
icon52-Week Low25.98000
iconAverage Volume0.83M
iconDividend Yield--
iconP/E Ratio--
What does the Stockal+Disclaimer.pdf do?
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company is developing small molecule drug candidates primarily engineered to increase muscle function and contractility. Its lead drug candidate is Tirasemtiv, a fast skeletal troponin activator, which is in Phase III clinical trial in patients with amyotrophic lateral sclerosis. Tirasemtiv has been granted orphan drug designation and fast track status by the U.S. Food and Drug Administration and orphan medicinal product designation by the European Medicines Agency. The company is preparing for the commercialization of Tirasemtiv in North America and Europe, as well as has granted an option to Astellas Pharma Inc. for development and commercialization in other countries. The company has strategic alliances with Astellas Pharma Inc. to develop CK-2127107, a fast skeletal muscle activator that is in two ongoing Phase II clinical trials enrolling patients with spinal muscular atrophy and chronic obstructive pulmonary disease, as well as other indications associated with muscle weakness; and with Amgen Inc. to develop omecamtiv mecarbil, a novel cardiac muscle activator, which is in Phase III clinical trial in patients with heart failure. Amgen Inc. holds an exclusive worldwide license to develop and commercialize omecamtiv mecarbil with a sublicense held by Servier for commercialization in Europe and other countries; and Astellas Pharma Inc. holds an exclusive worldwide license to develop and commercialize omecamtiv mecarbil and related compounds. The company was founded in 1997 and is headquartered in South San Francisco, California.
Read More
How much money does Stockal+Disclaimer.pdf make?
News & Events about Stockal+Disclaimer.pdf.
Zolmax
1 year ago
Cytokinetics, Incorporated (NASDAQ:CYTK Get Rating) CEO Robert I. Blum sold 12,500 shares of the businesss stock in a transaction that occurred on Monday, June 12th. The shares were sold at an average price of $37.06, for a total transaction of $463,250.00. Following the transaction, the chief ...
TipRanks Financial Blog
1 year ago
In a report released yesterday, Chris Shibutani from Goldman Sachs reiterated a Buy rating on Cytokinetics (CYTK Research Report), with a price t... In a report released yesterday, Chris Shibutani from Goldman Sachs reiterated a Buy rating on Cytokinetics (CYTK &#8211...
Zolmax
1 year ago
Cytokinetics, Incorporated (NASDAQ:CYTK Get Rating) CEO Robert I. Blum sold 12,500 shares of the stock in a transaction dated Friday, April 28th. The shares were sold at an average price of $37.68, for a total value of $471,000.00. Following the completion of the sale, the chief executive officer ...
TipRanks Financial Blog
1 year ago
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Cytokinetics (CYTK Research Report) and Neurocri... Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Cytokinetics (CYTK Research Report) and Neurocrine...
Globe Newswire
1 year ago
Company Plans to Discontinue the Phase 3 Clinical Trial of Reldesemtiv After Data Monitoring Committee Found No Effect on Primary or Key Secondary Endpoints Cytokinetics to Host Conference Call and Webcast Today at 8:30 am Eastern Time SOUTH SAN FRANCISCO, Calif., March 31, 2023 (GLOBE NEWSWIRE) -- ...
Frequently Asked Questions
Frequently Asked Questions
What is Stockal+Disclaimer.pdf share price today?
plus_minus_icon
Can Indians buy Stockal+Disclaimer.pdf shares?
plus_minus_icon
How can I buy Stockal+Disclaimer.pdf shares from India?
plus_minus_icon
Can Fractional shares of Stockal+Disclaimer.pdf be purchased?
plus_minus_icon
What are the documents required to start investing in Stockal+Disclaimer.pdf stocks?
plus_minus_icon
What is today’s traded volume of Stockal+Disclaimer.pdf?
plus_minus_icon
What is today’s market capitalisation of Stockal+Disclaimer.pdf?
plus_minus_icon
What is the 52-Week High and Low Range of Stockal+Disclaimer.pdf?
plus_minus_icon
What percentage is Stockal+Disclaimer.pdf down from its 52-Week High?
plus_minus_icon
What percentage is Stockal+Disclaimer.pdf up from its 52-Week Low?
plus_minus_icon
Current Price
$56.41
$0.5
(0.89%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00